Laura Lobo-Selma

Laura Lobo-Selma

Auto-generated profile, based on publicly available information

Laura Lobo-Selma

Instituto de Biomedicina de Sevilla, Hospital Virgen del Rocío, 41013 Seville, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DDdaniel delgado-bellido
daniel delgado-bellido
JOJavier Oliver
Javier Oliver
MPMaría Victoria Vargas Padilla
María Victoria Vargas Padilla
LLLaura Lobo-Selma
Laura Lobo-Selma
ACAntonio Chacón-Barrado
Antonio Chacón-Barrado
ENRIQUE DE ALAVAENRIQUE DE ALAVA
ENRIQUE DE ALAVA
Tumor growth depends on the vascular system, either through the expansion of blood vessels or novel adaptation by tumor cells. One of these novel pathways is vasculogenic mimicry (VM), which is defined as a tumor-provided vascular system apart from endothelial cell-lined vessels, and its origin is partly unknown. It involves highly aggressive tumor cells expressing endothelial cell markers that line the tumor irrigation. VM has been correlated with high tumor grade, cancer cell invasion, cancer cell metastasis, and reduced survival of cancer patients. In this review, we summarize the most relevant studies in the field of angiogenesis and cover the various aspects and functionality of aberrant angiogenesis by tumor cells. We also discuss the intracellular signaling mechanisms involved in the abnormal presence of VE-cadherin (CDH5) and its role in VM formation. Finally, we present the implications for the paradigm of tumor angiogenesis and how targeted therapy and individualized studies can be applied in scientific analysis and clinical settings.